Intuitive Surgical, Inc. has finalized its acquisition of the distribution operations for its da Vinci and Ion product lines from ab medica, Abex, and Excelencia Robótica. This strategic move, announced on March 2, integrates the acquired businesses into Intuitive Surgical's European commercial and marketing framework, marking a significant step in the company's direct operational expansion across Europe. This development is expected to bolster Intuitive Surgical's presence in the European market, particularly in countries like Italy, Spain, and Portugal, where a substantial number of da Vinci surgical systems are already in use.
The acquisition allows Intuitive Surgical to assume full ownership of the da Vinci and Ion distribution channels previously managed by its partners. By incorporating these operations directly, the company aims to streamline its sales, marketing, and support services in key European regions. This integration is crucial for enhancing customer relationships and optimizing the delivery of its robotic-assisted surgical and endoluminal systems.
As of late 2025, the combined installed base of da Vinci surgical systems across Italy, Spain, and Portugal had surpassed 470 units, demonstrating a strong existing market presence. Furthermore, the Ion endoluminal system, another innovative product from Intuitive Surgical, has recently been introduced in both Italy and Spain, indicating a growing portfolio and expanding market reach within Europe.
In a separate but related development, Intuitive Surgical's da Vinci 5 system received clearance from the U.S. Food and Drug Administration (FDA) on January 26. This clearance specifically covers certain complex cardiac procedures, including mitral valve repair and internal mammary artery (IMA) mobilization for cardiac revascularization. This regulatory approval underscores the continuous innovation and clinical versatility of Intuitive Surgical's technology, broadening its applicability in advanced surgical interventions.
Intuitive Surgical, Inc. is recognized for its comprehensive suite of products and services designed to provide robotic-assisted surgical solutions and support for minimally invasive care. Its core offerings include the highly acclaimed da Vinci Surgical systems and the innovative Ion Endoluminal platform, which together form an extensive ecosystem aimed at transforming surgical practices and improving patient outcomes globally.
The completed acquisition and the recent FDA clearance highlight Intuitive Surgical's commitment to growth and innovation in the global medical technology sector. By strengthening its direct operational footprint in Europe and expanding the clinical applications of its advanced surgical systems, Intuitive Surgical is poised to further solidify its leadership in robotic-assisted surgery, contributing to advancements in patient care and surgical efficiency worldwide.